Compare
Collegium Pharmaceutical vs Johnson & Johnson (COLL vs JNJ)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Collegium Pharmaceutical (COLL) returned -32.5% and Johnson & Johnson (JNJ) +48.5%; so far this year the figures are -47.7% and +33.5%.
Johnson & Johnson is the larger company by market value, about 886.6 times the size of Collegium Pharmaceutical.
On trailing earnings, COLL trades at 24.2 times and JNJ at 41.9 times.
Revenue grew +7.7% at COLL and +7.8% at JNJ over the last year.
COLL pays no dividend. JNJ yields 1.91%.
Data as of the latest close. Not investment advice.
Relative performance
| COLL | JNJ | |
|---|---|---|
| Price | $24.21 | $276.22 |
| 1-day | -3.78% | +1.43% |
| YTD | -47.71% | +33.47% |
| 1 year | -32.47% | +48.51% |
| 3 years | +11.06% | +85.77% |
| Market cap | $750M | $665.0B |
| P/E | 24.2 | 41.9 |
| P/S | 0.92 | 6.69 |
| P/B | 2.54 | 8.16 |
| Revenue growth | +7.70% | +7.80% |
| EPS growth | -37.90% | -36.40% |
| Gross margin % | 59.0 | 67.6 |
| Net margin % | 4.7 | 16.2 |
| ROE % | 12.9 | 19.7 |
| Debt / equity | 0.05 | 0.55 |
| FCF yield % | 44.7 | 3.1 |
| Dividend yield % | — | 1.91 |
| Beta | 0.11 | -0.09 |
| RSI (14) | 56.8 | 59.4 |
| Technical rating |